RxDoctor Payments Data

Everett Allen, MD

Rheumatology · San Antonio, TXNPI 1609846641

Payments from drug & device makers

$25,910in general payments, 2019–2025

Across 1,110 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$2K
  • UCB, Inc.$2K
  • Novartis$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • Invivyd Inc$1K
  • plus $11K from 40 others

What the payments were for

  • Consulting fees$1,3835%
  • Food & beverage$24,05593%
  • Education$4732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,910 in reported general payments places this provider in the 70th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$3,713,552
Medicare patients
830
Services billed
229,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept82$722,429
Orencia ClickjectAbatacept30$217,464
EnbrelEtanercept18$190,613
Cosentyx Sensoready (2 Pens)Secukinumab17$186,565
Humira(Cf) PenAdalimumab25$160,427
RinvoqUpadacitinib15$91,175
Actemra ActpenTocilizumab13$31,461
Hydroxychloroquine Sulfate309$8,695
MethotrexateMethotrexate Sodium386$8,031
Leflunomide85$2,415
Risedronate Sodium22$2,104
Prednisone273$1,976
Duloxetine Hcl126$1,948
Colchicine15$1,892
Azathioprine32$1,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$5,489$190,61318 claims
AbbVieRinvoq$533$91,17515 claims
Scilex Pharmaceuticals Inc.Colchicine$29$1,89215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 512 rheumatology providers in Texas.

Other rheumatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →